Insights

Blog Post | 03.04.26

Let’s Talk FCA: Gender-Affirming Care and Anti-DEI Executive Orders

Blog Post | 08.12.25

Legal Challenges to the One Big Beautiful Bill Act’s Restrictions on Federal Medicaid Funding

Blog Post | 07.18.25

CMS Issues FY 2026 Hospital IPPS Proposed Rule and LTCH PPS Proposed Rule

Blog Post | 07.18.25

Not So Surprising: The Fifth Circuit Finds No Private Right of Action in the No Surprises Act

Blog Post | 07.08.25

DOJ and HHS Launch FCA Working Group: Heightened Enforcement Risk for Health Care Entities

Blog Post | 06.18.25

CMS Innovation Center Releases New Strategy In Line With “MAHA” Agenda

Blog Post | 05.15.25

MAHA’s Vision for Healthier Diets: Awaiting Concrete Steps and Assessing Challenges

Blog Post | 05.15.25

Recent Federal Cases on Information Blocking Violations Pave Way for State Court Claims and Shed Light on Manner Exception

Blog Post | 05.07.25

The Role of Federal and State Governments in Maintaining Healthcare During Natural Disasters

Blog Post | 04.29.25

Seventh Circuit Clarifies Limits on Advertising Payments under the AKS

Blog Post | 01.31.25

FDA Releases Final Guidance on 510(k) Third Party Review Program and Third Party Emergency Use Authorization (EUA) Review

Blog Post | 01.31.25

House Task Force on AI Issues Report and Proposes Healthcare Recommendations

Blog Post | 01.30.25

FDA Clarifies Enforcement Policy Around Communications of Scientific Information on Unapproved Uses of Drugs and Medical Devices

Blog Post | 01.29.25

FDA Proposes Framework to Assess AI Model Output Credibility to Support Regulatory Decision-Making

Blog Post | 01.15.25

AMA’s CPT Editorial Panel Approves New Codes Covering Remote Patient Monitoring Services

Blog Post | 11.26.24

RCE Issues Technical Guidance Governing TEFCA Exchange

Blog Post | 11.14.24

HHS Releases Final Guidance for the Second Cycle of the Medicare Drug Price Negotiation Program

Blog Post | 11.05.24

Stringent Requirements for Pleading Fraud Under Rule 9(b).

Blog Post | 11.01.24

General Allegations Without Representative Examples Are Insufficient to Survive a Motion to Dismiss

Blog Post | 10.30.24

CMS Innovation Center Seeks Feedback on Medicare $2 Drug List Model